Meinol completed the B round financing of over 100 million yuan, and continued to accelerate the overall layout of CXO industry

Recently, Suzhou Meinuo Pharmaceutical Technology Co., LTD. (hereinafter referred to as "Meinuo Pharmaceutical") announced the completion of more than 100 million yuan of B round of financing, this round of financing by Hankang Capital led by Yida Capital, Yuanhe Holdings and other institutions to follow the investment.

This round of fundraising will be used to meet the growing small molecule drug CDMO business development and commercial production needs of the strategic layout, improve the company's research and development center and talent team building.

Founded in December 2008, Meinol Pharmaceutical is a platform enterprise with small molecule drug research and development as the core, providing integrated services from research and development, production and commercialization. It has a business center in the United States, a research and development center in Suzhou, a research and development center in Hefei, and a pilot and commercial production base in Shandong. The total number of employees is more than 400. With several core platforms, including Rethinking PROTAC and CDMO, Meinol maintains deep cooperation with the world's leading large pharmaceutical companies and biomedical companies.

Dr. Yanong Wang, Chairman and founder of Meinol, said:

Many thanks to Hankang Capital, the lead investor of this round, and other investors such as Yida Capital, Yuanhe Holdings and other new and old shareholders for the long-term recognition and firm support of Minuo Pharmaceutical. After years of unremitting efforts, Meinol has transformed its early research and development service of small molecule drugs into a comprehensive research and development and production platform. The successful completion of this round of financing will accelerate the company's positioning in the growing demand for small molecule CDMO and commercial production, and help Mino to take a more solid step towards becoming a leading CXO complex chemical company in China.

Founder, Chairman and President of Mino
Dr. Daniel Y. Wang

Mr. Yuan Quanhong, Founding Partner and Chief Executive Officer of Hankang Capital, said:

After 15 years of development, Meinol Pharmaceutical is committed to creating an integrated service ecosystem of research and development and production of small molecule innovative drugs. Meinol has built a service platform for the whole industry chain from drug synthesis, structure optimization, process development, comprehensive quality research, pilot test to cGMP commercial production. Hankang Capital will unswervably continue to support the development of Minopharma, and also looks forward to its rapid development in the field of small molecule drug CDMO and commercial production demand, to provide more comprehensive and better services for the majority of biomedical enterprises.

It's about Meinol

Meinol Pharmaceutical is a platform enterprise focusing on the whole industrial chain of small molecule chemicals. It was founded in 2008 by a returned technical team with more than 20 years of research and development and management experience in the world's famous pharmaceutical enterprises. The company is headquartered in Suzhou Industrial Park and has wholly-owned subsidiaries in Hefei, Shandong and the United States. Adhering to the corporate vision of "continuous technological innovation and high quality health escort", Meinol has always been rooted in China and with a global perspective, providing full life cycle services from preclinical drug design to commercial production, and striving to become the world's leading CXO company for complex chemical drugs.

About Hankang Capital

Hankang Capital is a venture capital fund focused on the pharmaceutical and health industry. With the mission of "enabling medical innovation and protecting human health", the foundation works with leading scientists and entrepreneurs to develop breakthrough new drugs to treat major diseases. With a foothold in China and a global vision, Hankang Capital has invested in a number of companies that have grown into industry leaders, such as Norshing Jianhua (09969.HK, SH), Kangfang Bio (09926.HK), Kangnoya Bio (02162.HK), Microcore Bio (688321.SH), Heyu Pharmaceutical (02256.HK), Opumai (688293.SH), etc.

About Atlas Capital

Founded by the internal mixed ownership reform of Jiangsu High-tech Investment Group, Yida Capital is one of the most influential venture capital institutions in China, ranking firmly in the forefront of the industry in terms of industry research ability, asset management scale and investment specialization.

The big health industry is the industry that Yida Capital focuses on and invests in. In recent years, Yida Capital focuses on the layout of bio-pharmaceutical, medical service, innovative devices, precision medicine and other subdivisions, and has cultivated a large number of well-known enterprises with core competitiveness in the industry. Including Shanghai Yizhong (688091), Haoyuan Pharmaceutical (688131), Shengxiang Biological (688289), Hua Hundsenwu (688639), etc.

About Yuanhe Holdings

Since its establishment in 2001, Yuanhe Holdings has focused on the field of equity investment, with a fund scale of over 100 billion yuan under management. It is one of the leading equity investment institutions in China. Since its establishment, it has focused on investment opportunities in emerging industries such as integrated circuits, biomedicine, artificial intelligence and nanotechnology application, and insisted on supporting real industries to promote industrial transformation and upgrading. At present, direct investment projects more than 1250, Yuan He mother fund investment sub-fund 153.